medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2009, Number 6

<< Back Next >>

Rev Invest Clin 2009; 61 (6)

Glycation and protein crosslinking in the diabetes and ageing pathogenesis

Cárdenas-León M, Díaz-Díaz E, Argüelles-Medina R, Sánchez-Canales P, Díaz-Sánchez V, Larrea F

Language: Spanish
References: 166
Page: 505-520
PDF size: 235.43 Kb.


ABSTRACT

Long exposition to hyperglycemia is associated with development of vascular diseases in diabetic patients. Many of these effects are mediated by non-enzymatic glycosylation (glycation) of proteins and formation of advanced glycation endproducts (AGEs). This phenomenon is accelerated in conditions where glucose concentration is chronically high, as it happens in diabetes mellitus. AGE formation is associated with structure-function alterations of proteins such as collagen, and particularly in tissues where these products are accumulated. A number of studies have demonstrated that AGEs can act as mediators, not only for the development of chronic complications of diabetes, but also in those related to ageing, nephropathy, Alzheimer’s disease and erectile dysfunction, among others. In this paper, information generated about formation and accumulation of AGEs, including its biological effects and their participation in the development of complications in diabetes mellitus and other process such as ageing is revised. In addition, therapeutic strategies and a new methodology to measure glycation products are also considered.


REFERENCES

  1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14 (Suppl. 5): S1-S85

  2. Rodríguez CK, Céspedes ME. Estrés oxidativo y envejecimiento. Rev Cubana Invest Biomed 1999; 18: 67-76.

  3. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314: 403-8.

  4. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-42.

  5. Nakayama H, Mitsuhashi T, Kuwajima S, Aoki S, Kuroda Y, Itoh T, et al. Immunochemical detection of advanced glycation end products in lens crystallins from streptozotocin-induced diabetic rat. Diabetes 1993; 42: 345-50.

  6. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck- Johnsen T, et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995; 44: 824-9.

  7. Shikata K, Makino H, Sugimoto H, Kushiro M, Ota K, Akiyama K, et al. Localization of advanced glycation endproducts in the kidney of experimental diabetic rats. J Diabetes Complications 1995; 9: 269-71.

  8. Nishino T, Horii Y, Shiiki H, Yamamoto H, Makita Z, Bucala R, et al. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Hum Pathol 1995; 26: 308-13.

  9. Sakai H, Jinde K, Suzuki D, Yagame M, Nomoto Y. Localization of glycated proteins in the glomeruli of patients with diabetic nephropathy. Nephrol Dial Transplant 1996; 11 (Suppl. 5): 66-71.

  10. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med 1996; 28: 419-26.

  11. Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R, Hanssen KF. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 1997; 46: 661-5.

  12. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 1997; 99: 1272-80.

  13. Yanagisawa K, Makita Z, Shiroshita K, Ueda T, Fusegawa T, Kuwajima S, et al. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism 1998; 47: 1348-53.

  14. Brownlee M. Negative consequences of glycation. Metabolism 2000; 49: 9-13.

  15. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, et al. A breaker of advanced glycation end products attenuates diabetes- induced myocardial structural changes. Circ Res 2003; 92: 785- 92.

  16. Nakamura S, Tachikawa T, Tobita K, Aoyama I, Takayama F, Enomoto A, et al. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats. Am J Kidney Dis 2003; 41: S68-S71.

  17. Miura J, Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications 2003; 17: 16-21.

  18. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535-42.

  19. Brownlee M. The pathology of diabetic complications: a unifyin mechanism. Diabetes 2005; 54: 1615-25.

  20. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-68.

  21. Díaz AD. Hiperglicemia y estrés oxidativo en el paciente diabético. Rev Cubana Invest Biomed 2006; 25: 1-10.

  22. Ceriello A. Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes, Nutrition & Metabolism 1999; 12: 42-6.

  23. Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002; 51: 597-604.

  24. Actis DS, Rebolledo OR. La glicación y glicoxidación de las lipoproteínas su importancia en la diabetes mellitus. Medicina (Buenos Aires) 2000; 60: 645-56.

  25. Maillard LC. Action des acides amines sur les sucres: formation des malaniodines par voice methodique. C R Acad Sci 1912; 154: 66-8.

  26. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984; 101: 527-37.

  27. Monnier VM, Cerami A. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 1981; 211: 491-3.

  28. Eble AS, Thorpe SR, Baynes JW. Nonenzymatic glucosylation and glucose-dependent cross-linking of protein. J Biol Chem 1983; 258: 9406-12.

  29. Monnier VM, Stevens VJ, Cerami A. Maillard reactions involving proteins and carbohydrates in vivo: relevance to diabetes mellitus and aging. Prog Food Nutr Sci 1981; 5: 315-27.

  30. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-21.

  31. Kikuchi S, Shinpo K, Takeuchi M, Yamagishi S, Makita Z, Sasaki N, et al. Glycation:a sweet tempter for neuronal death. Brain Res Rev 2003; 41: 306-23.

  32. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004; 95: 233-8.

  33. Booth AA, Khalifah RG, Todd P, Hudson BG. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 1997; 272: 5430-7.

  34. Ahmed N, Thornalley PJ. Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. Biochem Soc Trans 2003; 31: 1417-22.

  35. Vlassara H, Brownlee M, Cerami A. Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts. J Exp Med 1984; 160: 197-207.

  36. Vlassara H, Bucala R. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 1996; 45(Suppl. 3): S65-S66.

  37. Ahmed N. Advanced glycation endproducts: role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67: 3-21.

  38. Baynes WJ, Thorpe RS. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 1999; 48: 1-9.

  39. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991; 10: 339-52.

  40. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei- Jadidi R, et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003; 375: 581-92.

  41. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2006; 21: 197-208.

  42. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994; 94: 110-7.

  43. Bunn HF, Higgins PJ. Reaction of monosaccharides with proteins: possible evolutionary significance. Science 1981; 213: 222-24.

  44. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441-5.

  45. Cervantes-Laurean D, Jacobson EL, Jacobson MK. Glycation and glycoxidation of histones by ADP-ribose. J Biol Chem 1996; 271: 10461-9.

  46. Mitsuhashi T, Nakayama H, Itoh T, Kuwajima S, Aoki S, Atsumi T, et al. Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. Diabetes 1993; 42: 826-32.

  47. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143: 1649-56.

  48. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004; 104: 1287-91.

  49. Miyata S, Monnier V. Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. J Clin Invest 1992; 89: 1102-12.

  50. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 1992; 41: 1286-92.

  51. Al-Abed Y, Kapurniotu A, Bucala R. Advanced glycation end products: detection and reversal. Methods Enzymol 1999; 309: 152-72.

  52. Gomes R, Sousa Silva M, Quintas A, Cordeiro C, Freire A, Pereira P, et al. Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy. Biochem J 2005; 385: 339-45.

  53. Shibayama R, Araki N, Nagai R, Horiuchi S. Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction. Diabetes 1999; 48: 1842-9.

  54. Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001; 276: 48967-72.

  55. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N epsilon-( carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995; 34: 10872-8.

  56. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsiloncarboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261: 4889-94.

  57. Dunn JA, Patrick JS, Thorpe SR, Baynes JW. Oxidation of glycated proteins: age-dependent accumulation of N epsilon- (carboxymethyl)lysine in lens proteins. Biochemistry 1989; 28: 9464-8.

  58. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995; 270: 10017-26.

  59. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. The Endocrine Society 2001: 1-21.

  60. Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005; 289: F645-F659.

  61. Al-Abed Y, Bucala R. Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts. Bioconjug Chem 2000; 11: 39-45.

  62. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267: 5133-8.

  63. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997; 272: 16498-506.

  64. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816-22.

  65. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-5004.

  66. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988; 240: 1546-8.

  67. Miyazaki A, Nakayama H, Horiuchi S. Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc Med 2002; 12: 258-62.

  68. Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A 2004; 101: 11767-72.

  69. Stitt AW, He C, Vlassara H. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem Biophys Res Commun 1999; 256: 549-56.

  70. Tamura Y, Adachi H, Osuga J, Ohashi K, Yahagi N, Sekiya M, et al. FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J Biol Chem 2003; 278: 12613-7.

  71. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740-9.

  72. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.

  73. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-43.

  74. Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 2007; 13: 625-35.

  75. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-55.

  76. Sakurai S, Yamamoto Y, Tamei H, Matsuki H, Obata K, Hui L, et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 2006; 73: 158-65.

  77. Koyama Y, Takeishi Y, Niizeki T, Suzuki S, Kitahara T, Sasaki T, et al. Soluble Receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J Card Fail 2008; 14: 133-9.

  78. Grossin N, Wautier MP, Meas T, Guillausseau PJ, Massin P, Wautier JL. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab 2008; 34: 392-5.

  79. Bucala R, Vlassara H. Advanced glycosylation endproducts in diabetic renal disease: clinical measurement, pathophysiological significance, and prospects for pharmacological inhibition. Blood Purif 1995; 13: 160-70.

  80. Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract 1998; 41: 131-7.

  81. Miyata T, Sugiyama S, Suzuki D, Inagi R, Kurokawa K. Increased carbonyl modification by lipids and carbohydrates in diabetic nephropathy. Kidney Int Suppl 1999; 71: S54-S56.

  82. Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: a Nephrologist’s perspective. Am J Kidney Dis 2000; 35: 365-80.

  83. Ling X, Nagai R, Sakashita N, Takeya M, Horiuchi S, Takahashi K. Immunohistochemical distribution and quantitative biochemical detection of advanced glycation end products in fetal to adult rats and in rats with streptozotocin-induced diabetes. Lab Invest 2001; 81: 845-61.

  84. Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 1998; 9: 1681-8.

  85. Kanauchi M, Nishioka H, Dohi K. Serum levels of advanced glycosylation end products in diabetic nephropathy. Nephron 2001; 89: 228-30.

  86. Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 2005; 6: 453-74.

  87. Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, et al. Advanced glycation end products in Alzheimer’s disease and other neurodegenerative diseases. Am J Pathol 1998; 153: 1149- 55.

  88. Diamanti-Kandarakis E, Piperi C, Patsouris E, Korkolopoulou P, Panidis D, Pawelczyk L, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007; 127: 581-9.

  89. Jiaan DB, Seftel AD, Fogarty J, Hampel N, Cruz W, Pomerantz J, et al. Age-related increase in an advanced glycation end product in penile tissue. World J Urol 1995; 13: 369-75.

  90. Usta MF, Tuncer M, Baykal A, Ciftcioglu MA, Erdogru T, Koksal IT, et al. Impact of chronic renal failure and peritoneal dialysis fluids on advanced glycation end product and iNOS levels in penile tissue: an experimental study. Urology 2002; 59: 953-7.

  91. Koksal IT, Usta MF, Akkoyunlu G, Toptas B, Gulkesen KH, Erdogru T, et al. The potential role of advanced glycation end product and iNOS in chronic renal failure-related testicular dysfunction. An experimental study. Am J Nephrol 2003; 23: 361-8.

  92. Suji G, Sivakami S. Glucose, glycation and aging. Biogerontology 2004; 5: 365-73.

  93. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 1976; 295: 417-20.

  94. Cohen MP, Ziyadeh FN. Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol 1996; 7: 183-90.

  95. Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 1996; 737: 195-200.

  96. Tanaka S, Avigad G, Brodsky B, Eikenberry EF. Glycation induces expansion of the molecular packing of collagen. J Mol Biol 1988; 203: 495-505.

  97. Vlassara H, Palace MR. Glycoxidation: the menace of diabetes and aging. Mt Sinai J Med 2003; 70: 232-41.

  98. Monnier VM, Glomb M, Elgawish A, Sell DR. The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution. Diabetes 1996; 45 (Suppl. 3): S67-72.

  99. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A 1984; 81: 583-7.

  100. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999; 22: 1543-8.

  101. Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem 1992; 267: 12404-7.

  102. Cohen MP, Ziyadeh FN, Hong SW, Shearman CW, Hud E, Lautenslager GT, et al. Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF-beta1. Kidney Int 2002; 61: 2025-32.

  103. Peppa M, Uribarri J, Vlassara H. Glucose, advanced glycation end products, and diabetes complications: what is new and what works. Clin Diabetes 2003; 21: 186-7.

  104. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab (Paris) 2001; 27: 535-42.

  105. Bierhaus A, Hofmann AM, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovascular Research 1998; 37: 586-600.

  106. Basta G, Lazzerini G, Del Turco S, Ratto GM, Schmidt AM, De Caterina R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol 2005; 25: 1401-07.

  107. Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 2000; 278: F676-F683.

  108. Simm A, Munch G, Seif F, Schenk O, Heidland A, Richter H, et al. Advanced glycation endproducts stimulate the MAP-kinase pathway in tubulus cell line LLC-PK1. FEBS Lett 1997; 410: 481-4.

  109. Cohen MP, Shea E, Chen S, Shearman CW. Glycated albumin increases oxidative stress, activates NF-(kappa)B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-(beta) 1 production in macrophage RAW cells. J Lab Clin Med 2003; 141: 242-49.

  110. Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin- derived advanced glycosylation end products. Circ Res 2000; 86: E50-E54.

  111. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 1994; 91: 7742-6.

  112. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with noninsulin- dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567-74.

  113. Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H. Roles of the receptor for advanced glycation endproducts in diabetes- induced vascular injury. J Pharmacol Sci 2005; 97: 305-11.

  114. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-97.

  115. Gugliucci A, Bendayan M. Histones from diabetic rats contain increased levels of advanced glycation end products. Biochem Biophys Res Commun 1995; 212: 56-62.

  116. Kaneto H, Fujii J, Myint T, Miyazawa N, Islam KN, Kawasaki Y, et al. Reducing sugars trigger oxidative modification and apoptosis in pancreatic beta-cells by provoking oxidative stress through the glycation reaction. Biochem J 1996; 320 (Pt 3): 855-63.

  117. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 1996; 97: 1422-8.

  118. Nagai R, Fujiwara Y, Mera K, Otagiri M. Investigation of pathways of advanced glycation end-products accumulation in macrophages. Mol Nutr Food Res 2007; 51: 462-7.

  119. Abdel-Wahab YH, O´Harte FP, Ratcliff H, McClenaghan NH, Barnett CR, Flatt PR. Glycation of insulin in the islets of Langerhans of normal and diabetic animals. Diabetes 1996; 45: 1489-96.

  120. Lindsay JR, McKillop AM, NçMooney M, O´Harte FP, Bell PM, Flatt PR. Demonstration of increased concentrations of circulating glycated insulin in human type 2 diabetes using a novel and specific radioimmunoassay. Diabetologia 2003; 46: 475-78.

  121. Rubio-Ruiz ME, Díaz-Díaz E, Cárdenas-León M, Arguelles-Medina R, Sánchez-Canales P, Larrea-Gallo F, et al. Glycation does not modify bovine serum albumin (BSA)-induced reduction of rat aortic relaxation: the response to glycated and nonglycated BSA is lost in metabolic syndrome. Glycobiology 2008; 18: 517-25.

  122. Takata K, Horiuchi S, Araki N, Shiga M, Saitoh M, Morino Y. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J Biol Chem 1988; 263: 14819-25.

  123. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, et al. Macrophage Scavenger Receptor Mediates the Endocytic Uptake and Degradation of Advanced Glycation End Products of the Maillard Reaction. European J Biochem 2004; 230: 408-15.

  124. Horiuchi S, Higashi T, Ikeda K, Saishoji T, Jinnouchi Y, Sano H, et al. Advanced glycation end products and their recognition by macrophage and macrophage-derived cells. Diabetes 1996; 45(Suppl.) 3: S73-S76.

  125. Svistounov D, Smedsrod B. Hepatic clearance of advanced glycation end products (AGEs): myth or truth? J Hepatol 2004; 41: 1038-40.

  126. Lapolla A, Fedele D, Seraglia R, Traldi P. The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes: an update. Mass Spectrom Rev 2006; 25: 775-97.

  127. Gugliucci A, Mehlhaff K, Kinugasa E, Ogata H, Hermo R, Schulze J, et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta 2007; 377: 213-20.

  128. Sano H, Higashi T, Matsumoto K, Melkko J, Jinnouchi Y, Ikeda K, et al. Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products. J Biol Chem 1998; 273: 8630-7.

  129. Singh R, Barden A, Mori T, Beilin L. Advanced glycation endproducts: a review. Diabetologia 2001; 44: 129-46.

  130. Gonzalez M, Paquien C, Asenjo S, Gleisner A, Kirsten L, Bustamante M. [Autoantibodies against advanced glycation products in patients with type 1 diabetes mellitus]. Rev Med Chil 2001; 129: 141-8.

  131. Brownlee M. Pharmacological modulation of the advanced glycosylation reaction. Prog Clin Biol Res 1989; 304: 235-48.

  132. Kochakian M, Manjula BN, Egan JJ. Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes 1996; 45: 1694-700.

  133. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40.

  134. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 1986; 232: 1629-32.

  135. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 1991; 88: 11555-8.

  136. Zimmerman GA, Meistrell M, 3rd, Bloom O, Cockroft KM, Bianchi M, Risucci D, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A 1995; 92: 3744-8.

  137. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post- Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999; 257: 251-8.

  138. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-50.

  139. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997; 46: 895-9.

  140. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 2002; 51: 3283-9.

  141. Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826-32.

  142. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin- converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-87.

  143. Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H. Angiotensin II augments advanced glycation end product- induced pericyte apoptosis through RAGE overexpression. FEBS 2005; 579: 4265-70.

  144. Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose– induced angiotensin II production in rat vascular smooth muscle cells. Circulation Res 2007; 101: 455-61.

  145. Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY. Advanced glycation end products activate a chymasedependent angiotensin II–generating pathway in diabetic complications. Circulation 2006;113:1353-60.

  146. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000; 301: 65-77.

  147. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005; 16: 3631-41.

  148. Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Med Hypotheses 2006; 66: 1019-21.

  149. Ahmad MS, Ahmed N. Antiglycation properties of aged garlic extract: possible role in prevention of diabetic complications. J Nutr 2006; 136: 796S-799S.

  150. Babu PV, Sabitha KE, Shyamaladevi CS. Therapeutic effect of green tea extract on oxidative stress in aorta and heart of streptozotocin diabetic rats. Chem Biol Interact 2006; 162: 114-20.

  151. Cervantes-Laurean D, Schramm DD, Jacobson EL, Halaweish I, Bruckner GG, Boissonneault GA. Inhibition of advanced glycation end product formation on collagen by rutin and its metabolites. J Nutr Biochem 2006; 17: 531-40.

  152. Zhang J, Slevin M, Duraisamy Y, Gaffney J, C AS, Ahmed N. Comparison of protective effects of aspirin, D-penicillamine and vitamin E against high glucose-mediated toxicity in cultured endothelial cells. Biochim Biophys Acta 2006; 1762: 551-7.

  153. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998; 95: 4630-4.

  154. Usta MF, Kendirci M, Gur S, Foxwell NA, Bivalacqua TJ, Cellek S, et al. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med 2006; 3: 242-50; discussion 250-2.

  155. Cooper ME, Thallas V, Forbes J, Scalbert E, Sastra S, Darby I, et al. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000; 43: 660-4.

  156. Coughlan MT, Thallas-Bonke V, Pete J, Long DM, Gasser A, Tong DC, et al. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 2007; 148: 886-95.

  157. Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003; 419: 89-96.

  158. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-20.

  159. Li F, Drel VR, Szabo C, Stevens MJ, Obrosova IG. Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. Diabetes 2005; 54: 1514-22.

  160. Okamoto H, Nomura M, Nakaya Y, Uehara K, Saito K, Kimura M, et al. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med 2003; 42: 655-64.

  161. Figarola JL, Scott S, Loera S, Tessler C, Chu P, Weiss L, et al. LR- 90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 2003; 46: 1140-52.

  162. Haupt E, Ledermann H, Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy—a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005; 43: 71-7.

  163. Bucala R, Cerami A. Characterization of antisera to the addition product formed by the nonenzymatic reaction of 16 alpha- hydroxyestrone with albumin. Mol Immunol 1983; 20: 1289-92.

  164. Izuhara Y, Miyata T, Ueda Y, Suzuki D, Asahi K, Inagi R, et al. A sensitive and specific ELISA for plasma pentosidine. Nephrol Dial Transplant 1999; 14: 576-80.

  165. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994; 46: 216-22.

  166. Jakus V, Baynes JW. Chromatographic methods for assaying glycation, advanced glycation and glycoxidation In: Proccedings of 11th International Symposium: Advances and Applications of Chromatography in Industry. Bratislava; 2001, 27-31.




2020     |     www.medigraphic.com